The renal anemia market will expand over our 2016-2026 study period, fueled by increasing prevalence and a high unmet need for drugs that can effectively, safely, and conveniently control the disease. A series of hypoxia inducible factor prolyl hydroxylase ( HIF-PH ) inhibitors are expected to launch over the study period, which will promote market growth. However, these novel therapies will have to demonstrate safety and efficacy benefits over current therapies in order to succeed. Among the HIF - PH inhibitors, the most advanced agent is FibroGen/AstraZeneca/Astellas’s roxadustat, which is the subject of several long-term Phase III trials. Although these new therapies are expected to demonstrate advantages over current therapies, they will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment.
- What opportunities exist for the marketers of the emerging oral HIF-PH inhibitors to promote their noninvasive route of administration, particularly for patients not on dialysis?
- Will establishing cardiovascular ( CV ) safety be key for the market uptake of HIF-PH inhibitors, due to the CV issues associated with current therapies?
- With the imminent availability of biosimilars in the United States, will emerging therapies offering only incremental improvements over existing therapies struggle?
- What do key opinion leaders think about the iron-based phosphate binder Auryxia for the treatment of renal anemia?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.